Maria Chiara Chindamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Chiara Chindamo has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Cristiane Alves Villela Nogueira
Department of Internal Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil
4 shared publications - Luciana Agoglia
Department of Internal Medicine, Faculty of Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ Brazil; Section of Gastroenterology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brazil
3 shared publications - Marcos Arêas Marques
Universidade Federal do Estado do Rio de Janeiro, Brasil; Universidade do Estado do Rio de Janeiro, Brasil
3 shared publications - Sueli Carneiro
Universidade Federal do Rio de Janeiro
3 shared publications - Ana Carolina Cardoso
Hospital Universitário Clementino Fraga Filho, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
2 shared publications - Cecília Schubert Xavier Lagalhard Victer
Universidade Federal do Rio de Janeiro
2 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 456-461
Psoríase e risco cardiovascular: fatores associados e protetores
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 456-461
Open AccessPsoríase e risco cardiovascular: fatores associados e protetores
- Open Access
- 12 March 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 456-461
Psoriasis and cardiovascular risk: associated and protective factors
- 12 March 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 456-461
Open AccessPsoriasis and cardiovascular risk: associated and protective factors
- Open Access
- 14 February 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29 (4) , 101477
Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
- 14 February 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29 (4) , 101477
Open AccessPsoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
- Open Access
- 29 June 2023
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 4 (1) , 36-41
Cytomegalovirus esophagitis associated with gastroesophageal reflux disease in an immunocompetent patient: case report
Cytomegalovirus infection has a wide variability of clinical presentations depending on the patient's immunity, ranging from asymptomatic infections in immunocompetent individuals to infections with significant morbidity and mortality in immunocompromised patients. We originally described a clinical case of severe cytomegalovirus esophagitis, confirmed by blood polymerase chain reaction (PCR) test and esophageal biopsy, in a young immunocompetent patient with a long-standing diagnosis of gastroesophageal reflux disease. Clinical improvement occurred only after the initiation of specific treatment with ganciclovir, providing a negative viral load. This report reinforces the importance of ruling out the etiology of cytomegalovirus infection in severe ulcerative esophagitis, even in immunocompetent individuals.
- 29 June 2023
- Published by Publicacoes Cientificas de Acesso Aberto e Editora LTDA in Brazilian Journal of Case Reports
- Vol. 4 (1) , 36-41
Open AccessCytomegalovirus esophagitis associated with gastroesophageal reflux disease in an immunocompetent patient: case report
Cytomegalovirus infection has a wide variability of clinical presentations depending on the patient's immunity, ranging from asymptomatic infections in immunocompetent individuals to infections with significant morbidity and mortality in immunocompromised patients. We originally described a clinical case of severe cytomegalovirus esophagitis, confirmed by blood polymerase chain reaction (PCR) test and esophageal biopsy, in a young immunocompetent patient with a long-standing diagnosis of gastroesophageal reflux disease. Clinical improvement occurred only after the initiation of specific treatment with ganciclovir, providing a negative viral load. This report reinforces the importance of ruling out the etiology of cytomegalovirus infection in severe ulcerative esophagitis, even in immunocompetent individuals.
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 21
Challenges of extended venous thromboembolism prophylaxis in medical and surgical patients
Patients hospitalized for acute medical and surgical illnesses are at risk of developing venous thromboembolism (VTE) during hospitalization and after discharge. Extended pharmacological prophylaxis beyond the hospital stay is recommended for patients undergoing surgeries at high risk for VTE and for selected groups of hospitalized medical patients. This practice involves several challenges, from identification of at-risk populations eligible for extended prophylaxis to choice of the most appropriate anticoagulant and definition of the ideal duration of use. This review will present the main VTE risk assessment models for hospitalized medical and surgical patients, the current recommendations for use of extended prophylaxis, and its limitations and benefits.
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 21
Open AccessChallenges of extended venous thromboembolism prophylaxis in medical and surgical patients
Patients hospitalized for acute medical and surgical illnesses are at risk of developing venous thromboembolism (VTE) during hospitalization and after discharge. Extended pharmacological prophylaxis beyond the hospital stay is recommended for patients undergoing surgeries at high risk for VTE and for selected groups of hospitalized medical patients. This practice involves several challenges, from identification of at-risk populations eligible for extended prophylaxis to choice of the most appropriate anticoagulant and definition of the ideal duration of use. This review will present the main VTE risk assessment models for hospitalized medical and surgical patients, the current recommendations for use of extended prophylaxis, and its limitations and benefits.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 20
Avaliação do risco de sangramento na profilaxia do tromboembolismo venoso
Resumo O tromboembolismo venoso (TEV) é uma das principais causas preveníveis de morbimortalidade em pacientes hospitalizados, sendo a embolia pulmonar (EP) fatal possivelmente a sua primeira manifestação. Diretrizes nacionais e internacionais recomendam o uso de modelos de avaliação de risco para a prescrição de profilaxia do TEV em pacientes hospitalizados. Apesar das evidências e diretrizes de apoio, o uso da tromboprofilaxia permanece abaixo do ideal, o que pode resultar da baixa conscientização dos benefícios da profilaxia, mas também pode refletir o medo de complicações hemorrágicas, justificando a subutilização da tromboprofilaxia em todo o mundo. A avaliação do risco de sangramento é, portanto, necessária para a adequação de profilaxia e deve ser realizada de forma concomitante à avaliação do risco de trombose. O objetivo desta revisão é salientar a importância da avaliação conjunta do risco de TEV e do risco de sangramento em pacientes hospitalizados.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 20
Open AccessAvaliação do risco de sangramento na profilaxia do tromboembolismo venoso
Resumo O tromboembolismo venoso (TEV) é uma das principais causas preveníveis de morbimortalidade em pacientes hospitalizados, sendo a embolia pulmonar (EP) fatal possivelmente a sua primeira manifestação. Diretrizes nacionais e internacionais recomendam o uso de modelos de avaliação de risco para a prescrição de profilaxia do TEV em pacientes hospitalizados. Apesar das evidências e diretrizes de apoio, o uso da tromboprofilaxia permanece abaixo do ideal, o que pode resultar da baixa conscientização dos benefícios da profilaxia, mas também pode refletir o medo de complicações hemorrágicas, justificando a subutilização da tromboprofilaxia em todo o mundo. A avaliação do risco de sangramento é, portanto, necessária para a adequação de profilaxia e deve ser realizada de forma concomitante à avaliação do risco de trombose. O objetivo desta revisão é salientar a importância da avaliação conjunta do risco de TEV e do risco de sangramento em pacientes hospitalizados.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 18, e20180107
Papel da deambulação na prevenção do tromboembolismo venoso em pacientes clínicos: onde estamos?
Resumo O tromboembolismo venoso (TEV), que compreende o espectro de manifestações de trombose venosa profunda e/ou embolia pulmonar, é uma complicação comum, grave e evitável em pacientes hospitalizados. Embora a perda da mobilidade recente ou continuada represente um dos principais fatores de risco relacionados ao desenvolvimento de TEV, não existem critérios claros e uniformes para a definição do conceito de imobilidade. A diversidade dessas descrições dificulta a interpretação e a comparação dos resultados de estudos clínicos randomizados no que se refere à influência dos diferentes níveis de imobilidade na magnitude do risco de TEV e ao papel da deambulação precoce, de forma isolada, na prevenção de tais eventos. O entendimento dessas limitações é mandatório para a utilização e interpretação adequadas das ferramentas de avaliação de risco de TEV, e para a indicação da melhor estratégia de prevenção de trombose em pacientes clínicos hospitalizados. O objetivo deste estudo é revisar as principais evidências da literatura quanto ao papel da deambulação na prevenção do TEV.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 18, e20180107
Open AccessPapel da deambulação na prevenção do tromboembolismo venoso em pacientes clínicos: onde estamos?
Resumo O tromboembolismo venoso (TEV), que compreende o espectro de manifestações de trombose venosa profunda e/ou embolia pulmonar, é uma complicação comum, grave e evitável em pacientes hospitalizados. Embora a perda da mobilidade recente ou continuada represente um dos principais fatores de risco relacionados ao desenvolvimento de TEV, não existem critérios claros e uniformes para a definição do conceito de imobilidade. A diversidade dessas descrições dificulta a interpretação e a comparação dos resultados de estudos clínicos randomizados no que se refere à influência dos diferentes níveis de imobilidade na magnitude do risco de TEV e ao papel da deambulação precoce, de forma isolada, na prevenção de tais eventos. O entendimento dessas limitações é mandatório para a utilização e interpretação adequadas das ferramentas de avaliação de risco de TEV, e para a indicação da melhor estratégia de prevenção de trombose em pacientes clínicos hospitalizados. O objetivo deste estudo é revisar as principais evidências da literatura quanto ao papel da deambulação na prevenção do TEV.
- Open Access
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 9 (6) , 310-317
Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 9 (6) , 310-317
Open AccessFibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
- Open Access
- 1 September 2015
- Published by Elsevier in Annals of Hepatology
- Vol. 14 (5) , 652-657
Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists’ expertise
- 1 September 2015
- Published by Elsevier in Annals of Hepatology
- Vol. 14 (5) , 652-657
Open AccessIntermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists’ expertise
- 1 May 2002
- Published by Spandidos Publications in Oncology Reports
- Vol. 9 (3) , 657-659
Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphomas
Several studies have suggested an association between hepatitis C virus (HCV) and low-grade B-cell non-Hodgkin's lymphomas. The results, however, have been controversial. Italian and Japanese studies have reported a 40% prevalence rate, but the data were not confirmed by English and Canadian studies. We evaluated the prevalence of HCV infection in 109 patients with non-Hodgkin's lymphomas, and compared it with a control group composed of 67 patients with Hodgkin's disease and 31 patients with chronic lymphocytic leukemia. The prevalence of HCV infection was also determined in blood donors. HCV infection was detected using second and third generation anti-HCV ELISA. Positive results were additionally confirmed using Inno-LIA AbIII and/or RNA-HCV by PCR. Immunohistochemical stains were used to determine B or T cell lineage when the morphological analysis was not sufficient for lymphoma classification. HCV infection was detected in 9% of patients with non-Hodgkin's lymphomas, in 2% of patients in the control group (p=0.036), and in 1.2% of blood donors. There was no difference in the prevalence of HCV infection between patients with B or T cell lymphomas. Blood transfusions or previous surgeries, both risk factors for HCV infection, were detected in 90% of the patients with a positive anti-HCV test, in average 17 and 36 years before the diagnosis of lymphoma, respectively. Seventy percent of the patients with non-Hodgkin's lymphomas and a positive anti-HCV test presented evidence of chronic liver disease when the lymphoma was diagnosed. This study suggests the presence of an association between HCV infection and non-Hodgkin's lymphomas in Brazil.
- 1 May 2002
- Published by Spandidos Publications in Oncology Reports
- Vol. 9 (3) , 657-659
Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphomas
Several studies have suggested an association between hepatitis C virus (HCV) and low-grade B-cell non-Hodgkin's lymphomas. The results, however, have been controversial. Italian and Japanese studies have reported a 40% prevalence rate, but the data were not confirmed by English and Canadian studies. We evaluated the prevalence of HCV infection in 109 patients with non-Hodgkin's lymphomas, and compared it with a control group composed of 67 patients with Hodgkin's disease and 31 patients with chronic lymphocytic leukemia. The prevalence of HCV infection was also determined in blood donors. HCV infection was detected using second and third generation anti-HCV ELISA. Positive results were additionally confirmed using Inno-LIA AbIII and/or RNA-HCV by PCR. Immunohistochemical stains were used to determine B or T cell lineage when the morphological analysis was not sufficient for lymphoma classification. HCV infection was detected in 9% of patients with non-Hodgkin's lymphomas, in 2% of patients in the control group (p=0.036), and in 1.2% of blood donors. There was no difference in the prevalence of HCV infection between patients with B or T cell lymphomas. Blood transfusions or previous surgeries, both risk factors for HCV infection, were detected in 90% of the patients with a positive anti-HCV test, in average 17 and 36 years before the diagnosis of lymphoma, respectively. Seventy percent of the patients with non-Hodgkin's lymphomas and a positive anti-HCV test presented evidence of chronic liver disease when the lymphoma was diagnosed. This study suggests the presence of an association between HCV infection and non-Hodgkin's lymphomas in Brazil.